Selected article for: "liver enzyme and lopinavir ritonavir hiv combination"
Author: Lepage, Marc-Antoine; Rozza, Nicholas; Kremer, Richard; Grunbaum, Ami
Title: Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series
  • Cord-id: bzhvqyi2
  • Document date: 2021_3_1
    • ID: bzhvqyi2
    Snippet: CONTEXT: Originally developed for treatment of human immunodeficiency virus (HIV), the antiviral combination lopinavir/ritonavir (LPV/r) is being repurposed for treating the novel coronavirus disease (COVID-19) despite minimal experience in this markedly different population and an in-vitro derived EC50 against SARS-CoV-2 several hundred-fold greater than for HIV. We present a case series including a case of severe hyponatremia and a 32-fold overdose raising safety and effectiveness concerns in
    Document: CONTEXT: Originally developed for treatment of human immunodeficiency virus (HIV), the antiviral combination lopinavir/ritonavir (LPV/r) is being repurposed for treating the novel coronavirus disease (COVID-19) despite minimal experience in this markedly different population and an in-vitro derived EC50 against SARS-CoV-2 several hundred-fold greater than for HIV. We present a case series including a case of severe hyponatremia and a 32-fold overdose raising safety and effectiveness concerns in COVID-19 patients. METHODS: We measured LPV trough concentrations in 12 patients and reviewed their clinical charts for side effects known to occur in HIV patients. FINDINGS: Compared to established LPV trough concentrations in HIV patients, concentrations in COVID-19 patients were 3-fold greater (19.37 ± 10.12 mcg/mL versus 6.25 mcg/mL). In addition, cholestasis and dyslipidemia toxicity thresholds were exceeded in 12/12 and 11/12 patients respectively. No patients achieved the presumed therapeutic concentration. Side effects included gastrointestinal symptoms (5/12), electrolyte imbalances (4/12), liver enzyme disturbances (5/12) and triglyceride elevations (2/12). CONCLUSION: No patients reached presumed therapeutic LPV concentrations despite experiencing side effects and exceeding cholestasis and dyslipidemia toxicity thresholds. This raises concerns for the safety and effectiveness of LPV/r. Clinicians should consider closely monitoring for side effects and not necessarily attribute them to COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acutely ill: 1
    • abdominal pain and adrenal insufficiency: 1, 2, 3, 4, 5
    • abdominal pain and adrenal insufficiency diagnosis: 1, 2, 3
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • acalculous cholecystitis and acute respiratory syndrome: 1, 2, 3, 4
    • accidental overdose and acute respiratory syndrome: 1
    • acute infection and adrenal insufficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute infection and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and low metabolic: 1
    • acute inflammatory phase and lopinavir ritonavir: 1
    • acute respiratory syndrome and adrenal insufficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low metabolic: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir and lpv concentration: 1, 2, 3